Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review Article

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

List of authors.
  • Michael A. Postow, M.D.,
  • Robert Sidlow, M.D.,
  • and Matthew D. Hellmann, M.D.

The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Postow reports receiving grant support, paid to his institution, and consulting fees from Bristol-Myers Squibb, honoraria from Merck and Bristol-Myers Squibb, and consulting fees and advisory board fees from Novartis, Ono Pharmaceutical, Array BioPharma, Merck, Incyte, and NewLink Genetics; and Dr. Hellmann, receiving consulting fees and advisory board fees from Genentech, Merck, AstraZeneca, Novartis, Janssen, and Mirati Therapeutics and grant support, consulting fees, and advisory board fees from Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.

Author Affiliations

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.

Address reprint requests to Dr. Postow at 300 East 66th St., New York, NY 10065, or at .

Print Subscriber? Activate your online access.